VERU vs. XERS, NUS, NATR, MED, EL, IPAR, PBH, HLF, USNA, and NGNE
Should you be buying Veru stock or one of its competitors? The main competitors of Veru include Xeris Biopharma (XERS), Nu Skin Enterprises (NUS), Nature's Sunshine Products (NATR), Medifast (MED), Estée Lauder Companies (EL), Inter Parfums (IPAR), Prestige Consumer Healthcare (PBH), Herbalife (HLF), USANA Health Sciences (USNA), and Neurogene (NGNE).
Veru (NASDAQ:VERU) and Xeris Biopharma (NASDAQ:XERS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, community ranking, risk, earnings, media sentiment, institutional ownership and dividends.
Veru has a beta of -0.43, meaning that its share price is 143% less volatile than the S&P 500. Comparatively, Xeris Biopharma has a beta of 2.72, meaning that its share price is 172% more volatile than the S&P 500.
Veru currently has a consensus target price of $4.00, suggesting a potential upside of 321.72%. Xeris Biopharma has a consensus target price of $4.63, suggesting a potential upside of 77.20%. Given Veru's higher possible upside, research analysts clearly believe Veru is more favorable than Xeris Biopharma.
Xeris Biopharma has a net margin of -37.58% compared to Veru's net margin of -265.27%. Veru's return on equity of -130.13% beat Xeris Biopharma's return on equity.
Veru received 129 more outperform votes than Xeris Biopharma when rated by MarketBeat users. However, 69.80% of users gave Xeris Biopharma an outperform vote while only 69.59% of users gave Veru an outperform vote.
47.2% of Veru shares are owned by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are owned by institutional investors. 14.2% of Veru shares are owned by company insiders. Comparatively, 4.6% of Xeris Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Veru had 1 more articles in the media than Xeris Biopharma. MarketBeat recorded 3 mentions for Veru and 2 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 0.96 beat Veru's score of 0.48 indicating that Xeris Biopharma is being referred to more favorably in the news media.
Xeris Biopharma has higher revenue and earnings than Veru. Xeris Biopharma is trading at a lower price-to-earnings ratio than Veru, indicating that it is currently the more affordable of the two stocks.
Summary
Veru beats Xeris Biopharma on 9 of the 16 factors compared between the two stocks.
Get Veru News Delivered to You Automatically
Sign up to receive the latest news and ratings for VERU and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VERU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
